Randox Discovery
Randox Discovery
Randox Discovery | The Benchtop Lab
Discover The Future Of Molecular & Immunoassay Diagnostics
Why Choose the Discovery?
- The Discovery is an exciting and disruptive analyser capable of molecular and immunoassay testing
- Simultaneous detection of hundreds of targets from a single patient sample via patented biochip technology
- Flexible test menu comprising immunoassay and genetic tests for infectious diseases & oncology
- Rapid turnaround time. Three hours to first batch of results with results for subsequent batches every hour after
- Fully automated platform increasing operator walkaway time. A single operator is all that’s required to run up to 3 Discovery analysers
- Simple and easy to use. Intuitive user interface guides the operator through the entire testing process
Discover The Power Of Automation
Randox Discovery is comprised of three interconnected modules which each operate independently performing different aspects of the diagnostic testing process. Each module is separated by a physical barrier to prevent contamination and is accessible via a door. The workflow process runs from right to left and is compatible with lean working principles.
Nucleic Acid Extraction
Module I is responsible for DNA/RNA extraction. After extraction the sample is automatically transferred to Module II. Before transfer, Module I detects the presence of Module II cartridges using a unique vision system.
Multiplex PCR
Module II is responsible for amplification of the extracted nucleic acid by End-Point PCR. UV light is used to sterilise the module and reduce the risk of crossover contamination.
Biochip Hybridisation & Detection
Module III is used in both immunoassay & molecular workflows and is responsible for hybridisation and subsequent detection using patented biochip technology. The detection camera uniquely moves between sample cartridges to detect biochip chemiluminescence.
Discover the Power of Randox Biochip Technology
The Randox Discovery is an exciting and disruptive molecular & immunoassay diagnostic analyser capable of consolidating the normal workload of multiple laboratories, into one compact benchtop platform. Randox patented Biochip Technology allows simultaneous detection of hundreds of targets from a single patient sample. The benefits of multiplexing in this way are endless; allows complete patient profiling, reduces the amount of time spent on individual tests, identifies co-infections, differentiates between pathogens that exhibit similar symptoms and eliminates the need to run multiple time consuming and sample intensive assays. The biochip detection system is based on a chemiluminescent signal, this is the emission of light, without heat, as a result of a chemical reaction.
Discover Our Comprehensive Test Menu
| VIRUSES | ||
| SARS-CoV-2 (COVID-19) | Sarbecovirus (SARS, SARS like, SARS-CoV-2) |
| Detectable Viruses | ||
|---|---|---|
| SARS-CoV-2 (COVID-19) | Sarbecovirus (SARS, SARS like, SARS-CoV-2) | Influenza A |
| Coronavirus 229E/NL63 | Adenovirus A/B/C/D/E | Influenza B |
| Coronavirus OC43/HKUI | Enterovirus A/B/C/D / Rhinovirus A/B/C | Respiratory Syncytial Virus A/B (RSV) |
| Middle East Respiratory Syndrome Coronavirus (MERS-CoV) | Adenovirus A/B/C/D/E | |
*In Development – Respiratory Tract Infections Array, Chronic Lung Infections Array, Sexually Transmitted Infections Array & Urinary Tract Infections Array, KRAS, BRAF & PIK3CA Array, Familial Hypercholesterolemia Array & Cardiac Risk Array.
*In Development – A number of clinical immunoassay arrays covering a range of disease markers including adhesion molecules, alzheimers, anaemia, bone disease, cancer, cardiac, cytokines, diabetes, endocrines, fibrinolysis, fertility, gastrointestinal, metabolic, renal, stroke, thyroid & tissue damage.
*In Development – A number of clinical toxicology arrays are in development covering a wide range of Drugs of Abuse (DoA) & New Psychoactive Substances (NPS) detecting over 500 drug and drug metabolites using innovative Biochip Technology.
Product availability may vary from country to country. Some product may be for Research use Only. For more information on product application and availability, please contact your local Randox Representative.
Discover Randox’s Molecular Platforms
All In One Point Of Care Molecular Platform
Compact, Semi-Automated Benchtop Analyser
Related Products
Qnostics
QCMD
Vivalytic
Evidence Investigator
Randox Extended Coronavirus Array: Bringing the Best Science to the Forefront
COVID-19 (2019-nCoV) was declared a global emergency of international concern. The WHO’s director-general’s greatest concern is the potential for COVID-19 to spread to countries with weaker health systems. The biggest catch with containing the epidemic of COVD-19 is the detection. It has been recognised that faulty kits have been shipped around America by the Centers for Disease Control and Prevention (CDC) and there simply aren’t enough kits in China 1. Randox can aid in overcoming these challenges.
What is COVID-19?
The COVID-19 is a new strain of coronavirus that has not been previously identified in humans. Consequently, research on this new strain is lacking. Symptoms are similar to that of the common cold or flu, including: fever, cough, difficultly breathing, muscle pain and fatigue. Like other respiratory infections, transmission occurs through respiratory droplets from coughing and sneezing, with an estimated incubation period of 2 to 14 days 2.
Current Situation
Globally, there are 46, 997 confirmed cases of COVID-19, with 46, 550 of these confirmed cases attributed to China. Only 447 of the total number of cases are outside of China, across 24 countries. The total number of deaths attributed to COVID-19 sits at 1, 369 of which all have been observed in China, except one. These statistics are laboratory-confirmed cases only 3. These statistics were reported by WHO on 13 February and is the situation of number, total and new cases, within the past 24hrs from being recorded. Whilst China is at a very high risk, the global risk level is high. These statistics indicate the necessity for COVID-19 diagnosis, especially as the above are only laboratory-confirmed cases combined with the faulty tests distributed in America and the lack of diagnostic tests in China.
The Randox Extended Coronavirus Array
Randox have developed a fast and accurate test for the detection of COVID-19, the new strain of coronavirus. The Randox Extended Coronavirus Array is the only test in the world that can identify the potentially lethal strain and differentiate between other respiratory pathogens with similar symptoms.
The new test utilises the Randox Biochip Technology, with results within 5 hours on the Randox Evidence Investigator, a semi-automated analyser capable of processing 54 patient samples simultaneously.
The Randox Coronavirus Array comprises five coronaviruses strains, including the COVID-19 (2019-nCoV) strain. The table below provides a breakdown of the viruses included in the Randox Extended Coronavirus Array:
Dr Peter FitzGerald, Managing Director of Randox Laboratories, commented;
“Current technologies for the diagnosis of coronavirus are designed simply to detect the presence or lack of COVID-19, and therefore neglect to differentiate between this strain and other respiratory infections. We have therefore developed an extended Viral Respiratory Infection Array that tests simultaneously for COVID-19 and nine other viruses. This will eliminate the need for multiple back-and-forth tests before the root cause of symptoms is found, and empower clinicians to make fast and informed decisions.”
Want to know more?
Contact us or download our coronavirus flyer
Related Products
Qnostics
QCMD
Biosciences
References
Coronavirus: A Global Health Emergency of International Concern
There is still a lot unknown about the 2019 novel coronavirus (2019-nCoV), however, current knowledge is mostly based on the intel of existing coronaviruses including Middle East Respiratory Syndrome (MERS-CoV) and Severe Acute Respiratory Syndrome (SARS-CoV) 1. Last week, the World Health Organization (WHO) declared the 2019-nCoV a global health emergency of international concern. The WHO’s director-general, Tedros Adhanom Ghebreyesus stated: “The main reason for this declaration is not because of what is happening in China but because of what is happening in other countries. Our greatest concern is the potential for this virus to spread to countries with weaker health systems, which are ill-prepared to deal with it” 2.
WHO recommend educating all and increasing knowledge of the 2019-nCoV. The aim of this article is to provide further information on the 2019-nCoV to aid in combatting the mass hysteria through education.
About the 2019-nCoV
The 2019-nCoV belongs to a large family of respiratory viruses with illnesses ranging from the common cold to more severe diseases such as MERS-CoV and SARS-CoV. 2019-nCoV is a new strain that has not been previously identified in humans 3. Coronaviruses are common in a variety of animal species including: bats, cats, cattle and camels 1. Coronaviruses are zoonotic which means the virus can be transmitted between animals and humans. SARS-CoV was transmitted from civet cats and MERS-CoV was transmitted from dromedary camels 3. Zoonotic viruses are commonplace with approximately 60% of current infectious diseases and 75% of all emerging infectious diseases in humans being zoonotic according to the UNEP Frontiers 2019 Report: Emerging Issues of Environmental Concern, with approximately one new infectious disease emerging in humans every four months 4.
2019-nCoV Transmission & Prevention
The exact origin of the 2019-nCoV is unknown and the analysis of the genetic trees of this virus is ongoing, however ‘it is important to note that person-to-person spread can happen on continuum’. Currently, it is unclear on how contagious the 2019-nCoV is 5. It is believed that the spread of the 2019-nCoV virus is similar to that of other respiratory pathogens (influenza). It is believed that the spread occurs via respiratory droplets produced when an infected person sneezes or coughs and lands in the mouth or noses or possibly inhaled into the lunch of people nearby (about 6 feet). It is unclear at this time if the 2019-nCoV can be caught via touching surfaces or objects that have the virus and then touching their nose, mouth and possibly eyes.
It is important to understand that the transmissibility and severity of viruses vary and there is still much to learn about the 2019-nCoV 6. Whilst there is no vaccine to prevent the transmissibility of the 2019-nCoV, daily steps can be taken to aid in the prevention of the spread, similar to that of respiratory infections in general 7:
1. Wash hands with soap and water for 20 seconds, especially after using the toilet, before eating, after blowing your nose, sneezing and coughing.
2. If soap and/or water is not readily available, alcohol-based (minimum 60% alcohol) hand sanitisers can be used.
3. Avoid toughing mouth, nose and eyes with unwashed hands.
4. Avoid close contact with those who are sick.
5. Stay at home when you are sick.
6. Always cover coughs and sneezing with a tissue and discard in a bin.
7. Clean and disinfect frequently touched objects and surfaces using a regular household cleaning wipe or spray.
It is vitally important to get tested if you believe you have the 2019-nCoV which can aid in preventing the further transmissibility of the virus.
Randox Coronavirus Arrays
Randox are developing a rapid test for the 2019-nCoV which will utilise the Randox Biochip Technology, with results available within 3 hours on the Vivalytic and with 5 hours on the Randox Evidence Investigator.
The Randox Novel Coronavirus Array detects the 2019-nCoV strain quickly and accurately, enabling effective and accurate medical protocols to be actioned.
The Randox Extended Coronavirus Array encompasses multiple strains of the coronaviruses including: 2019-nCoV, 229E, NL63, OC43 and HKUI. The wider panel provides a comprehensive coronavirus screening panel, enabling effective and accurate medical protocols to be actioned.
Want to know more?
Contact us or download our coronavirus flyer
Related Products
Qnostics
QCMD
Biosciences
References